Ricardo Correa‐Rotter

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 5.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Effects of Increased Peritoneal Clearances on Mortality Rates in Peritoneal Dialysis

Ramón Paniagua, Dante Amato, Edward F. Vonesh et al. · Journal of the American Society of Nephrology · 2002 · 964 citations

Medicine, Nephrology, Dialysis +15

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

David C. Wheeler, Bergur V. Stefánsson, Niels Jongs et al. · The Lancet Diabetes & Endocrinology · 2020 · 530 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson et al. · Kidney International · 2021 · 397 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis

Jean‐Jacques Body, Gregory Gaich, Wim H. Scheele et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 365 citations

Medicine, Pharmacotherapy, Bone Augmentation +16